New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Prelude Therapeutics Incorporated (PRLD) vs SAB Biotherapeutics, Inc. (SABS)

Prelude Therapeutics Incorporated and SAB Biotherapeutics, Inc. are both Biotechnology companies. Prelude Therapeutics Incorporated and SAB Biotherapeutics, Inc. are of similar size ($262.2M and $260.5M). Prelude Therapeutics Incorporated has the higher net margin (−247.1% vs −1,450.3%) and the higher return on invested capital (0.00% vs −48.4%). Across the 15 metrics below, Prelude Therapeutics Incorporated leads on 11 and SAB Biotherapeutics, Inc. on 4.

Valuation

Metric PRLD SABS Biotechnology median
P/E n/m n/m 8.49
P/S 15.44 161.56 8.56
P/B 2.68 1.25 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 8.95 99.47 8.00
Earnings yield (18.32%) (32.95%) (35.81%)
Free cash flow yield (8.40%) (22.34%) (25.41%)

Profitability

Metric PRLD SABS Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (283.92%) (1,647.03%) 0.00%
Net margin (247.12%) (1,450.32%) 0.00%
Free cash flow margin (129.68%) (1,344.29%) 0.00%
Return on equity (58.36%) (47.62%) (51.58%)
Return on assets (39.45%) (42.73%) (45.91%)
Return on invested capital 0.00% (48.38%) 0.00%

Growth

Metric PRLD SABS Biotechnology median
Revenue growth (TTM) — (56.68%) 7.20%
EPS growth (last fiscal year) 23.21% 78.53% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — (26.69%) 0.00%

Health

Metric PRLD SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 4.20 7.28 4.79
Net debt to EBITDA 1.00 2.03 1.01

Dividend

Metric PRLD SABS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PRLD SABS Biotechnology median
Market cap 260.48m 262.16m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack